Imperial Brands Plc Releases 2022 Annual Report

Nov.16.2022
Imperial Brands Plc Releases 2022 Annual Report
Imperial Brands Plc's 2022 annual report showed a decrease in revenue and operating income due to market exits and disposals.

On November 15, 2022, Imperial Brands Plc (formerly known as Imperial Tobacco Group), the fourth-largest tobacco company, released their annual report for the year ending on September 30, 2022. The following are the key points compiled by 2FIRSTS.


Photo source: Imperial Tobacco official website.


As of September 30, 2021, Imperial Brands reported a net revenue of £32.791 billion for the fiscal year 2022, representing a 0.7% decline compared to fiscal year 2021's revenue of £32.551 billion. The company also reported a revenue of £31.46 billion for 2022, reflecting a 14.7% YoY decline from 2021's revenue of £26.83 billion. The decline was attributed to costs related to the company's exit from the Russian and related markets (£399 million) and the disposal of its premium cigar division's non-recurring earnings (£281 million). The company's market share in the US cigarette market increased by 90 basis points to 10.1%, registering its fourth consecutive year of growth. YOY, adjusted operating profits in the Americas region increased by 5.8%. The five largest heated tobacco markets registered a combined 35 basis point increase in market share, while nicotine pouches performed significantly well in Sweden, Norway, and Austria. The company's NGP portfolio also exhibited strong performance in Europe, recording a 34.2% YoY net revenue increase. In contrast, Europe's adjusted operating profit fell by 5.2% when calculated with a fixed exchange rate. The UK market shrank by 11%, driven by the surge in illegal trade as borders reopened. The African market continued to perform exceptionally well, recording 3% increases in both market share and revenue. The company's Pulze and iD heated tobacco devices generated significant interest from trade partners and consumers during trial sales in the Czech Republic and Greece in 2021. As of 2022 and driven by growing demand, both products are now also available in Italy, Portugal, and Hungary. The company expects high growth potential in the Italian market, the largest heated tobacco market in Europe. Following successful trial launches in France, the company released a new e-cigarette device based on blu 2.0pod in the UK and added disposable products to the blu range. The company reported a 4.9% increase in adjusted earnings per share, driven by rising operating profits and declining interest costs. With a free cash flow of £2.6 billion for 2022, the company strengthened its balance sheet, enabling higher returns for shareholders. From October 2022, the company plans to return capital to shareholders through continuous share buybacks, with a promised initial buyback of £1 billion set to be completed by September 2023. Combining dividends and buybacks, the company expects to return over £2.3 billion in capital to shareholders in the next fiscal year. The company aims to accomplish its annual savings target of £150 million by the end of fiscal year 2023. Tobacco production dropped by 4.7% (excl. Russia: 1.2%).


Click here to download the original PDF of the 2022 Imperial Tobacco financial report.


Statement:


This article is for internal research and sharing within the industry only. It does not provide any investment or brand recommendations and should not be used as a basis for investment decisions. The data and analysis conclusions cited in this article have not been confirmed in writing by the company. Please refer to the company's official releases for all data.


This article is an original piece of work created by Shenzhen 2FIRSTS Technology Co., Ltd. The copyright and usage rights belong to the company and may not be reproduced or copied for commercial purposes without permission. Any unauthorized use will result in legal action taken by the company to protect its intellectual property.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
Product | BAT Expands VELO Travellers’ Collection With Mexico, Spain and Sweden Summer Edition Nicotine Pouches
British American Tobacco (BAT) Global Travel Retail has expanded the VELO Travellers’ Collection with three new Summer Editions: Mexico, Spain and Sweden. Inspired by destination themes, the new nicotine pouch variants are designed for global travel-retail channels. The launch further strengthens VELO’s positioning as a travel-retail exclusive product collection.
Aug.27